Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

It was an­i­mal da­ta on G1 Ther­a­peu­tics’ on­col­o­gy drug tri­laci­clib that orig­i­nal­ly at­tract­ed cur­rent CEO Mark Vel­le­ca to the com­pa­ny six years ago. And now the 5-year clin­i­cal so­journ — a quick turn in the R&D world — is near­ing the ini­tial goal line at the FDA.

On Mon­day, G1 — which was co-found­ed by NCI chief Ned Sharp­less — an­nounced the drug was grant­ed pri­or­i­ty re­view by the FDA for pa­tients with small cell lung can­cer. If ap­proved, the com­pa­ny hopes to roll out tri­laci­clib ear­ly next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.